Arvinas, Inc. (NASDAQ:ARVN) Receives $35.50 Average PT from Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $35.50.

Several brokerages recently weighed in on ARVN. HC Wainwright reissued a “buy” rating and issued a $81.00 price objective on shares of Arvinas in a report on Monday. Wedbush downgraded shares of Arvinas from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $57.00 to $12.00 in a report on Wednesday, March 12th. Morgan Stanley reduced their price target on shares of Arvinas from $48.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 13th. Guggenheim lowered their price objective on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th.

Arvinas Price Performance

Shares of Arvinas stock opened at $6.19 on Friday. Arvinas has a 1-year low of $6.00 and a 1-year high of $39.34. The company has a market capitalization of $425.70 million, a PE ratio of -2.23 and a beta of 2.30. The business has a 50-day moving average of $13.45 and a 200-day moving average of $19.64.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the business posted ($2.53) EPS. On average, equities analysts expect that Arvinas will post -3.81 earnings per share for the current fiscal year.

Insider Transactions at Arvinas

In related news, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at $945,097.57. This represents a 7.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,230 shares of company stock valued at $769,402. 5.23% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arvinas

A number of institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of Arvinas in the 4th quarter worth $28,000. KBC Group NV grew its holdings in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares during the period. GAMMA Investing LLC raised its position in Arvinas by 11,283.8% in the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock worth $300,000 after acquiring an additional 4,175 shares in the last quarter. Quantbot Technologies LP lifted its holdings in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Arvinas during the 4th quarter valued at about $171,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.